BMRN - BioMarin Pharmaceutical Inc.
| Previous Close | 76.00 |
| Open | 75.86 |
| Bid | 74.46 x 800 |
| Ask | 85.40 x 800 |
| Day's Range | 74.43 - 77.11 |
| 52 Week Range | 70.82 - 106.74 |
| Volume | 1,730,190 |
| Avg. Volume | 1,141,314 |
| Market Cap | 13.451B |
| Beta (3Y Monthly) | 1.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.62 |
| Earnings Date | Oct 23, 2019 - Oct 28, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 118.90 |
- GuruFocus.com
Gilead, AbbVie Are Innovative, but May Be Underappreciated
Companies need to demonstrate they can be successful in new therapeutic areas Continue reading...
- GuruFocus.com
Stocks That Fell to 3-Year Lows in the Week of Sept. 13
Altria Group Inc. (MO), BioMarin Pharmaceutical Inc. (BMRN), Pennant Park Investment Corp. (PNNT), and Rigel Pharmaceuticals Inc. (RIGL) have declined to their three-year lows Continue reading...
- Simply Wall St.
Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Overpaying Its CEO?
Jean-Jacques Bienaimé has been the CEO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) since 2005. First, this article...
- PR Newswire
BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York
SAN RAFAEL, Calif. , Sept. 9, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Dan Spiegelman , Executive Vice President and Chief Financial Officer and Henry Fuchs ...
- Zacks
BioMarin (BMRN) Down 7.3% Since Last Earnings Report: Can It Rebound?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 31% Discount?
Does the August share price for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reflect what it's really worth? Today, we...
- American City Business Journals
The $200K Club: NetApp's median employee gets a pay boost to join the salary ranks of Google, Netflix and Facebook
NetApp Inc. this year paid its median employee just shy of $200,000 — a level that puts it on par with some of Silicon Valley's biggest companies and represents a 26 percent jump, year-over-year.
- GuruFocus.com
6 Underperforming Stocks in Gurus' Portfolios
Concho Resources makes the list Continue reading...
- Zacks
Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval
Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year. The company plans expansion of gene therapy program into other indications including multiple sclerosis.
- Thomson Reuters StreetEvents
Edited Transcript of BMRN earnings conference call or presentation 1-Aug-19 8:30pm GMT
Q2 2019 Biomarin Pharmaceutical Inc Earnings Call
- Motley Fool
BioMarin's Roller Coaster Continues
Long-term investors need to learn to stomach the ride.
Motley FoolBiomarin Pharmaceutical Inc (BMRN) Q2 2019 Earnings Call Transcript
BMRN earnings call for the period ending June 30, 2019.
- Zacks
BioMarin (BMRN) Shares Down on Q1 Earnings & Sales Miss
BioMarin (BMRN) announces lower-than-expected earnings and revenues for the second quarter of 2019. It keeps its previously provided revenue guidance intact.
- Barrons.com
BioMarin Stock Dropped After Hours on Weak Earnings, but Analysts Aren’t Worried
The company lost 21 cents a share, while analysts had expected a loss of 11 cents a share, according to FactSet.
- Zacks
BioMarin Pharmaceutical (BMRN) Lags Q2 Earnings and Revenue Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of -47.06% and -5.63%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
BioMarin Announces Second Quarter 2019 Financial Results
- Total Revenues of $387.8 million in the Quarter - Full-year 2019 Total BioMarin Revenue Guidance of Between $1.68 billion to $1.75 billion Reaffirmed - As of June 30, 2019, 551 U.S. Commercial Patients ...
- Zacks
What's in the Cards for Sarepta (SRPT) This Earnings Season?
Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive second-quarter sales.
- Zacks
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- American City Business Journals
Health Care Digest: Why 2020 could be big for women's health, Trump's kidney order — and more
Myovant's plan to control heavy menstrual bleeding, how President Trump's executive order on kidney treatments could help a San Francisco company and more in our Health Care Digest.
- PR Newswire
BioMarin to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1 at 4:30pm ET
SAN RAFAEL, Calif. , July 16, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
- Markit
See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRNView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for BMRN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold BMRN had net inflows of $7.05 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Motley Fool
Shake-Up in Big Weed
One of the marijuana industry’s pioneers was just ousted from Canopy Growth. What comes next?
- Simply Wall St.
BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shift From Loss To Profit
BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN): BioMarin Pharmaceutical Inc., a biotechnology company, develops and...
